該当箇所へ

Genedata has Successfully Collaborated with Egis Pharmaceuticals PLC to Develop a Precision Medicine Tool for Rheumatoid Arthritis

A novel approach to guide infliximab therapy selection for rheumatoid arthritis patients

October 12, 2021
Basel, Switzerland and Budapest, Hungary

Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, and Egis Pharmaceuticals PLC (Egis), one of the leading European pharmaceutical companies, announce their collaboration to develop a precision medicine tool for rheumatoid arthritis.

Rheumatoid arthritis is a chronic autoimmune condition affecting around 1% of the worldwide population. Clinical therapeutic options are still limited in their efficacy. A large portion of patients fail to achieve low-disease activity using TNFα inhibitor biological treatments such as infliximab. This problem represents an unmet medical need for therapy efficacy prediction.

Recognizing the urgent need for an advanced precision therapy that provides a more effective treatment for this debilitating disease, Egis has developed the PREDYSTIC® Infliximab RA Kit, which received the CE In Vitro Diagnostic (IVD) Medical Device Certificate on December 21st, 2020. The Kit is based on gene expression biomarkers that can help to differentiate between responders and non-responders to infliximab before treatment initiation. The PREDYSTIC® Infliximab RA test even predicts the Disease Activity Score (DAS28 CRP) for the 6th month of the treatment.

As part of the collaboration, Genedata has provided Data Science services to Egis, hereby leveraging the power of Genedata Profiler®, the firm’s market-leading enterprise software for the harmonization, integration, management, and analysis of multi-omics, biomarker, clinical, and phenotypic data derived from translational and clinical research.

“An effective therapy for rheumatoid arthritis that works well for patients has long been an elusive goal,” commented Dr. Zsolt Holló, head of the Center of Biological Business Development and Technology at Egis Pharmaceuticals PLC. “With the scientific support of Genedata and its Genedata Profiler software, Egis has developed the PREDYSTIC® Infliximab RA Kit to guide the treatment of RA patients, allowing therapies to be matched to the patients who will derive true benefits from treatment. Within our partnership, the Genedata team has been crucial to achieving this aim.”

“I am excited to see how we and our innovative Genedata Profiler platform have been instrumental to the success of Egis,” said Othmar Pfannes, Ph.D., CEO of Genedata. “We believe the same approach can be successful in the development of precision medicines for many other immune-related indications, and where our expertise in analyzing complex patient profiles can be of immense value.”

Genedata is committed to contributing towards the discovery and development of new precision therapies and bringing those to underserved populations.

About Egis Pharmaceuticals PLC

Egis (member of the Servier Group) headquartered in Budapest, Hungary, is one of the leading generic pharmaceutical companies in Central and Eastern Europe. The company’s activities extend to every field of the pharmaceutical value chain: from Research and Development through the production of Active Pharmaceutical Ingredients and Finished Drug Products to sales and marketing. Egis products are available in 60 countries through the company’s network of subsidiaries and representative offices or partners. Egis launched the first biosimilar infliximab for the treatment of rheumatoid arthritis in Central and Eastern Europe in 2013.
More information about the PREDYSTIC® Infliximab RA Kit visit:
https://hu.egis.health/personalized-medicine
and
PREDYSTIC Showcase

Egis Contact

Dr. Zsolt Holló
Head, Center of Biological Business Development and Technology
Egis Pharmaceuticals PLC
Phone: +36306392133
e-mail: hollo.zsolt@egis.hu


With the scientific support of Genedata and its Genedata Profiler software, Egis has developed the PREDYSTIC® Infliximab RA Kit to guide the treatment of RA patients, allowing therapies to be matched to the patients who will derive true benefits from treatment.

Zsolt Holló, PhD.
Head of the Center of Biological Business Development and Technology